research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
The label change by the agency announcing dexrazoxane as an approved cardio-oncology protectant has been followed by a review by the agency. Currently, the only FDA and EMA approved cardioprotective treatment for anthracycline cardioprotection is dexrazoxane, which provides effective primary cardioprotection against anthracycline-induced cardiotoxicity without reducing anthracycline activity and without enhancing secondary malignancies. The United States Food and Drug Administration has also approved a dexrazoxane for use as a treatment of extravasation resulting from IV anthracycline chemotherapy. Extravasation is an adverse event in which chemotherapies containing anthracylines leak out of the blood vessel and necrotize the surrounding tissue.
In 2024, Meta released a collection of large AI models, including Llama 3.1 405B, which was competitive with less open models. Meta's description of Llama as open-source has been disputed due to Llama's software license, which prohibits it from being used for some purposes, and due to Meta not disclosing the origin of the data used to train the models. DeepSeek released their V3 LLM in December 2024, and their R1 reasoning model on 20 January 2025, both as open-weights models under the MIT license. This release made widely known how China had been embracing using and building more open AI systems as a way to reduce reliance on western software and gatekeeping as well as to help give its industries access to higher-powered AI more quickly. Projects based in China have since become more widely used around the world as well as they have closed at least some of the gap with leading proprietary American models. Since the release of OpenAI's proprietary ChatGPT model in late 2022, there have been only a few fully open (weights, data, code, etc.) large language models released. In September 2025, a Swiss consortium added to this short list by releasing a fully open model named Apertus. In December 2025, the Linux Foundation created the Agentic AI Foundation, which assumed control of some open-source agentic AI protocols and other technologies created by OpenAI, Anthropic and Block. Starting in November 2024, Lightricks began releasing the LTX video models as open weights.
Light therapy treatments for the skin usually involve exposure to ultraviolet light. The exposures can be to a small area of the skin or over the whole body surface, as in a tanning bed. The most common treatment is with narrowband UVB, which has a wavelength of approximately 311–313 nanometers. Full body phototherapy can be delivered at a doctor's office or at home using a large high-power UVB booth. Tanning beds, however, generate mostly UVA light, and only 4% to 10% of tanning-bed light is in the UVB spectrum.
Sources: en.wikipedia.org
Cold air damming typically happens in the mid-latitudes as this region lies within the Westerlies, an area where frontal intrusions are common. When the Arctic oscillation is negative and pressures are higher over the poles, the flow is more meridional, blowing from the direction of the pole towards the equator, which brings cold air into the mid-latitudes. Cold air damming is observed in the southern hemisphere to the east of the Andes, with cool incursions seen as far equatorward as the 10th parallel south. In the northern hemisphere, common situations occur along the east side of ranges within the Rocky Mountains system over the western portions of the Great Plains, as well as various other mountain ranges (such as the Cascades) along the west coast of the United States. The initial is caused by the poleward portion of a split upper level trough, with the damming preceding the arrival of the more equatorward portion. Some of the cold air damming events which occur east of the Rockies continue southward to the east of the Sierra Madre Oriental through the coastal plain of Mexico through the Isthmus of Tehuantepec. Further funneling of cool air occurs within the Isthmus, which can lead to winds of gale and hurricane-force, referred to as a Tehuantepecer. Other common instances of cold air damming take place on the coastal plain of east-central North America, between the Appalachian Mountains and Atlantic Ocean. In Europe, areas south of the Alps can be prone to cold air damming. In Asia, cold air damming has been documented near Taiwan and the Korean Peninsula.
BDPC (systematic name 4-(4-bromophenyl)-4-(dimethylamino)-1-(2-phenylethyl)cyclohexanol; also known as bromadol) is a potent fully synthetic opioid with a distinctive arylcyclohexylamine chemical structure. It was developed by Daniel Lednicer at Upjohn in the 1970s. Initial studies estimated that it was around 10,000 times the potency of morphine in animal models. However, later studies using more modern techniques assigned a value of 504 times the potency of morphine for the more active trans-isomer. This drug was first seized along with three kilograms of acetylfentanyl in an April 25, 2013 police action in Montreal, Canada, and has reportedly continued to be available on the designer drug market internationally. Analogues where the para-bromine is replaced by chlorine or a methyl group retain similar activity, while the meta-hydroxyl derivative demonstrated robust antagonist activity.
Radium was discovered by Marie Skłodowska-Curie and her husband Pierre Curie on 21 December 1898 in a uraninite (pitchblende) sample from Jáchymov. While studying the mineral earlier, the Curies removed uranium from it and found that the remaining material was still radioactive. In July 1898, while studying pitchblende, they isolated an element similar to bismuth which turned out to be polonium. They then isolated a radioactive mixture consisting of two components: compounds of barium, which gave a brilliant green flame color, and unknown radioactive compounds which gave carmine spectral lines that had never been documented before. The Curies found the radioactive compounds to be very similar to the barium compounds, except they were less soluble. This discovery made it possible for the Curies to isolate the radioactive compounds and discover a new element in them. The Curies announced their discovery to the French Academy of Sciences on 26 December 1898. The naming of radium dates to about 1899, from the French word radium, formed in Modern Latin from radius (ray): this was in recognition of radium's emission of energy in the form of rays. The gaseous emissions of radium, radon, were recognized and studied extensively by Friedrich Ernst Dorn in the early 1900s, though at the time they were characterized as "radium emanations". In September 1910, Marie Curie and André-Louis Debierne announced that they had isolated radium as a pure metal through the electrolysis of pure radium chloride (RaCl2) solution using a mercury cathode, producing radium–mercury amalgam.
Enterochromaffin-like cells or ECL cells are a type of neuroendocrine cell found in the gastric glands of the gastric mucosa beneath the epithelium, in particular in the vicinity of parietal cells, that aid in the production of gastric acid via the release of histamine. They are also considered a type of enteroendocrine cell.
Sources: en.wikipedia.org
== Climate == Based on the Köppen climate classification, Endless Chain Ridge is located in a subarctic climate with cold, snowy winters, and mild summers. Winter temperatures can drop below −20 °C with wind chill factors below −30 °C. Precipitation runoff from Endless Chain Ridge drains west to the Sunwapta River, or east into the Maligne River, both of which are tributaries of the Athabasca River.
For services to Young People on the Isle of Man. Walter Barry Pugh, lately Senior Storekeeper, Ministry of Defence. Joyce Winifred Pullen. For services to the Save the Children Fund in Wiltshire. Parveen Qureshi, Manager, Rotherham Multi-Cultural Centre. For services to the community. David Quinney, Station Officer, Central Scotland Fire Brigade. For services to the Fire Service. Ellen Elizabeth Redman. For services to the community in Malmesbury, Wiltshire. Cyril Redpath. For services to the Army Cadet Force in Northumbria. Lydia Elizabeth Reed, Main Executive, W.J.O. Jennings Ltd. For services to Public Transport. Alan Tait Rees. For services to the community in Edinburgh. Alistair Reid, Chairman, Scottish Fisherman's Organisation. For services to the Fisheries Industry Gwyn Rhydderch, Co-ordinator, British Arts Festivals Association. For services to the Arts. Dennis Richards. For charitable services in Penzance, Cornwall. Bryan Robert Riches, Sub-Divisional Officer, Suffolk Special Constabulary. For services to the. Police. Edmund Caerwyn Roberts. For services to Agriculture in Wales. John Aubrey Roberts. For services to the Wrexham Hospital League of Friends, North Wales. Moira Mary Ann Robertson, lately Custodian, Skara Brae. Eric Robinson. For charitable services in Nantwich, Cheshire. Jeremy John Lawrence Robinson, Senior Executive Officer, Ministry of Defence. John Robinson, Managing Director, S. Robinson & Sons (Eng.) Ltd. For services to the Construction Industry. Frank Rodgers. For services to the Environment in Derbyshire. David Gordon Rollo.
Spironolactone, also known as 7α-acetylthiospirolactone, is a steroidal 17α-spirolactone, or more simply a spirolactone. It can most appropriately be conceptualized as a derivative of progesterone, itself also a potent antimineralocorticoid, in which a hydroxyl group has been substituted at the C17α position (as in 17α-hydroxyprogesterone), the acetyl group at the C17β position has been cyclized with the C17α hydroxyl group to form a spiro 21-carboxylic acid γ-lactone ring, and an acetylthio group has been substituted in at the C7α position. These structural modifications of progesterone confer increased oral bioavailability and potency, potent antiandrogenic activity, and strongly reduced progestogenic activity. The C7α substitution is likely responsible for or involved in the antiandrogenic activity of spironolactone, as 7α-thioprogesterone (SC-8365), unlike progesterone, is an antiandrogen with similar affinity to the AR as that of spironolactone. In addition, the C7α substitution appears to be responsible for the loss of progestogenic activity and good oral bioavailability of spironolactone, as SC-5233, the analogue of spironolactone without a C7α substitution, has potent progestogenic activity but very poor oral bioavailability similarly to progesterone.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.